CIP
ANIP icon

Convergence Investment Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Convergence Investment Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,935
Closed -$141K – 228
2019
Q3 		$141K Sell
1,935
-65
-3% -$4.86K 0.04% 261
2019
Q2 		$164K Buy
+2,000
New +$142K 0.04% 276

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Convergence Investment Partners's ANIP Position: Q4 2019 in Review

Convergence Investment Partners sold out of ANI Pharmaceuticals (ANIP) in Q4 2019, closing a stake of 1,935 shares — an estimated $141K sold.

Convergence Investment Partners first reported a position in ANIP in Q2 2019 and held it in 2 quarters. The position peaked at $164K in Q2 2019. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

  • Convergence Investment Partners reported no remaining ANI Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 1,935 ANI Pharmaceuticals shares in Q4 2019, an estimated $141K.
  • Convergence Investment Partners first reported a position in ANI Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Convergence Investment Partners's ANI Pharmaceuticals position peaked at $164K in Q2 2019.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.